Save up -80% on Pergolide
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Permax
|price without discount in nearest pharmacy. Price may vary.|
We offer free Pergolide coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Pergolide every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Pergolide volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Pergolide
Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinsons Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.
Pergolide mechanism of action
The dopamine D sub2 /sub receptor is a 7-transmembrane G-protein coupled receptor associated with G subi /sub proteins. In lactotrophs, stimulation of dopamine D sub2 /sub receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca sup2+ /sup from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D sub2 /sub receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders.
Dosage forms of Pergolide
Permax Tab 0.05mg
Pergolida Pergolide Mesylate
Eli Lilly Canada Inc
Humans and other mammals
Indication of Pergolide
Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson‘s disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Pergolide on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.